Search

Your search keyword '"Fois, Sara S."' showing total 12 results
Start Over Author "Fois, Sara S."
12 results on '"Fois, Sara S."'

5. Prothrombin time (PT), international normalized rate (INR), and in-hospital mortality in COVID-19

Author

PALIOGIANNIS, Panagiotis, primary, ZINELLU, Angelo, additional, MANGONI, Arduino A., additional, PAZZOLA, Antonio, additional, BANDIERA, Francesco L., additional, SPANO, Antonio, additional, SANNA, Chiara, additional, SCANO, Valentina, additional, FOIS, Sara S., additional, MUSCAS, Verdiana, additional, MASOTTO, Elena, additional, DORE, Stefano, additional, FIORE, Vito, additional, PIRINA, Pietro, additional, CARRU, Ciriaco, additional, and FOIS, Alessandro G., additional

Published
2021
Full Text
View/download PDF

6. Vaccination Status and Number of Vaccine Doses Are Independently Associated with the PaO 2 /FiO 2 Ratio on Admission in Hospitalized COVID-19 Patients.

Author

Zinellu, Elisabetta, Zinellu, Angelo, Merella, Michela, Mangoni, Arduino A., Pau, Maria Carmina, Fois, Sara S., Fois, Alessandro G., Carru, Ciriaco, and Pirina, Pietro

Subjects
VACCINATION status, COVID-19, HOSPITAL patients, VACCINATION, COVID-19 testing
Abstract

Introduction: Coronavirus Disease-19 (COVID-19) vaccines reduce the risk of severe disease and mortality. However, the association between vaccination status and number of doses and the PaO2/FiO2 ratio, a clinical measure of hypoxemia associated with an increased risk of intensive care treatment and mortality, has not been investigated. Methods: We retrospectively assessed a consecutive series of 116 patients admitted to hospital with a primary diagnosis of COVID-19 between January and April 2022. Demographic, clinical, and laboratory data were collected within 24 h from admission. Results: There was a significant positive relationship between the number of vaccine doses and the PaO2/FiO2 ratio (r = 0.223, p = 0.012). This association remained significant after adjusting for confounders. Vaccinated patients had significantly higher PaO2/FiO2 ratios than the unvaccinated (median: 250; IQR: 195–309 vs. 200; IQR: 156–257, p = 0.013). Conclusion: These results highlight the importance of the number of vaccine doses received in reducing the degree of hypoxia on admission in hospitalized COVID-19 patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

9. Reliability and Usefulness of Different Biomarkers of Oxidative Stress in Chronic Obstructive Pulmonary Disease

Author

Zinellu, Elisabetta, Zinellu, Angelo, Fois, Alessandro G., Fois, Sara S., Piras, Barbara, Carru, Ciriaco, and Pirina, Pietro

Subjects
Article Subject
Abstract

Introduction. Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by airflow limitation that is not fully reversible after inhaled bronchodilator use associated with an abnormal inflammatory condition. The biggest risk factor for COPD is cigarette smoking. The exposure to noxious chemicals contained within tobacco smoke is known to cause airway epithelial injury through oxidative stress, which in turn has the ability to elicit an inflammatory response. In fact, the disruption of the delicate balance between oxidant and antioxidant defenses leads to an oxidative burden that has long been held responsible to play a pivotal role in the pathogenesis of COPD. There are currently several biomarkers of oxidative stress in COPD that have been evaluated in a variety of biological samples. The aim of this review is to identify the best studied molecules by summarizing the key literature findings, thus shedding some light on the subject. Methods. We searched for relevant case-control studies examining oxidative stress biomarkers in stable COPD, taking into account the analytical method of detection as an influence factor. Results. Many oxidative stress biomarkers have been evaluated in several biological matrices, mostly in the blood. Some of them consistently differ between the cases and controls even when allowing different analytical methods of detection. Conclusions. The present review provides an overview of the oxidative stress biomarkers that have been evaluated in patients with COPD, bringing focus on those molecules whose reliability has been confirmed by the use of different analytical methods.

Published
2020
Full Text
View/download PDF

10. Biomarkers of Oxidative Stress and Inflammation in Chronic Airway Diseases

Author

Chamitava, Liliya, primary, Cazzoletti, Lucia, additional, Ferrari, Marcello, additional, Garcia-Larsen, Vanessa, additional, Jalil, Aneza, additional, Degan, Paolo, additional, Fois, Alessandro G., additional, Zinellu, Elisabetta, additional, Fois, Sara S., additional, Fratta Pasini, Anna Maria, additional, Nicolis, Morena, additional, Olivieri, Mario, additional, Corsico, Angelo, additional, Bono, Roberto, additional, Pirina, Pietro, additional, and Zanolin, Maria Elisabetta, additional

Published
2020
Full Text
View/download PDF

12. Repurposing Anticancer Drugs for the Treatment of Idiopathic Pulmonary Fibrosis and Antifibrotic Drugs for the Treatment of Cancer: State of the Art

Author

Paliogiannis, Panagiotis, Fois, Sara S., Fois, Alessandro Giuseppe, Cossu, Antonio, Palmieri, Giuseppe, and Pintus, Gianfranco

Abstract

Idiopathic pulmonary fibrosis (IPF) is an aggressive pulmonary disease which shares several molecular, pathophysiological and clinical aspects with lung cancer, including high mortality rates. The antifibrotic drugs Nintedanib and Pirfenidone have recently been introduced in clinical practice for the treatment of IPF. Nintedanib is also used for the treatment of several malignancies, including non-small cell lung cancer (NSCLC) in combination with Docetaxel, while Pirfenidone showed some anti-neoplastic effects in preclinical studies. On the other hand, novel targeted agents and immunotherapies have been introduced in the last decade for the treatment of NSCLC, and some of them showed anti-fibrotic properties in recent studies. These evidences, based on the common pathophysiological backgrounds of IPF and lung cancer, make possible the mutual or combined use of anti-fibrotic and anti-neoplastic drugs to treat these highly lethal diseases. The aim of the present review is to depict the current scientific landscape regarding the repurposing of anti-neoplastic drugs in IPF and anti-fibrotic drugs in lung cancer, and to identify future research perspectives on the topic.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results